Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Dec;115(12):3318-25.
doi: 10.1172/JCI27071.

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

Affiliations
Review

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

Lawrence G Raisz. J Clin Invest. 2005 Dec.

Abstract

Osteoporosis is a disorder in which loss of bone strength leads to fragility fractures. This review examines the fundamental pathogenetic mechanisms underlying this disorder, which include: (a) failure to achieve a skeleton of optimal strength during growth and development; (b) excessive bone resorption resulting in loss of bone mass and disruption of architecture; and (c) failure to replace lost bone due to defects in bone formation. Estrogen deficiency is known to play a critical role in the development of osteoporosis, while calcium and vitamin D deficiencies and secondary hyperparathyroidism also contribute. There are multiple mechanisms underlying the regulation of bone remodeling, and these involve not only the osteoblastic and osteoclastic cell lineages but also other marrow cells, in addition to the interaction of systemic hormones, local cytokines, growth factors, and transcription factors. Polymorphisms of a large number of genes have been associated with differences in bone mass and fragility. It is now possible to diagnose osteoporosis, assess fracture risk, and reduce that risk with antiresorptive or other available therapies. However, new and more effective approaches are likely to emerge from a better understanding of the regulators of bone cell function.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The BMU with possible sites of estrogen action. Bone remodeling on the surface of trabecular bone is illustrated here. The process is similar in the haversian systems in cortical bone. Osteoclast activation is ordinarily initiated by an interaction of hematopoietic precursors with cells of the osteoblast lineage but may also be initiated by inflammatory cells, particularly T cells (see Figure 2 for further details). Once osteoclasts are formed, there is a resorption phase of limited duration and a brief reversal phase, during which the bone surface is covered by mononuclear cells but bone formation has not yet begun. The formation phase is then initiated, possibly by factors produced by the osteoclast or reversal cells or released from the bone matrix. The formation phase, which is substantially longer than the first 3 phases, involves the production of matrix by progressive waves of osteoblasts. These then become flat lining cells, are embedded in the bone as osteocytes, or undergo apoptosis. Potential sites of action of estrogen include effects on T cell cytokine production (i); effects on stromal or osteoblastic cells to alter their production of RANKL or OPG (ii); direct inhibition of differentiated osteoclasts (iii); and effects on bone formation mediated by osteoblasts or osteocytes to enhance the response to mechanical forces initiated by these cells (iv). Note that the BMU is shown as being compartmentalized by an overlying layer of cells. It has been proposed that these are separated lining cells, but they may be of vascular origin.
Figure 2
Figure 2
Regulation of osteoclast formation and activity. In physiologic remodeling, activation of bone resorption requires contact between cells of the osteoblast and osteoclast lineages. M-CSF, which may be either membrane bound or secreted, interacts with its receptor, c-fms, to stimulate differentiation and proliferation of hematopoietic progenitors, which then express RANK as preosteoclasts. Osteoclast differentiation and activity are stimulated by RANK/RANKL interaction, and this interaction can be blocked by soluble OPG. Bone-resorbing factors can also stimulate COX2 activity, which may amplify responses to RANKL and OPG by producing prostaglandins. In pathologic conditions, inflammatory and malignant cells can increase osteoclastogenesis by producing soluble or membrane-bound M-CSF and RANKL as well as PTH-related protein (PTHrP), cytokines, and prostaglandins.
Figure 3
Figure 3
Interaction of the Wnt, BMP, and sclerostin pathways. Differentiation of osteoblasts during both development and remodeling is dependent on the activity of both the Wnt and BMP pathways. Wnt signaling requires the interaction of the LRP5 and frizzled receptors (Frz) and can be inhibited by Dickkopf (DKK; an inhibitor of LRP5) and secreted frizzled-related protein (SFRP). Antagonists such as sclerostin can block both BMP and Wnt signaling. The mediator of the canonical Wnt pathway, β-catenin, can synergize with BMP2 to enhance osteoblast differentiation and bone formation. Consistent with these interactions are the findings that high bone mass can result both from activating mutations of the Wnt pathway and deletion of SOST, the gene encoding sclerostin.

Similar articles

Cited by

References

    1. Cooper, A., and Cooper, B.B. 1822. A treatise on dislocations, and on fractures of the joints. Churchill. London, United Kingdom. 425 pp. - PubMed
    1. Schapira D, Schapira C. Osteoporosis: the evolution of a scientific term. Osteoporos. Int. 1992;2:164–167. - PubMed
    1. Albright F, Bloomberg E, Smith PH. Postmenopausal osteoporosis. Trans. Assoc. Am. Physicians. 1940;55:298–305.
    1. Riggs BL, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J. Clin. Invest. 1982;70:716–723. - PMC - PubMed
    1. Liu YZ, Liu YJ, Recker RR, Deng HW. Molecular studies of identification of genes for osteoporosis: the 2002 update. J. Endocrinol. 2003;177:147–196. - PubMed

MeSH terms

  NODES
Note 1
twitter 2